GRCL News and Press, Gracell Biotechnologies Inc. From 08/16/21

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors PR Newswire SUZHOU and SHANGHAI, China , and PALO ALTO, Calif. , Aug. 16, 2021 /PRNewswire/ --...

SUZHOU, China and PALO ALTO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cance...

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...

SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma Webinar on June 11 2021 at 8:00am EDT PR Newswire ...

SUZHOU, China and PALO ALTO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tre...

Gainers: Annovis Bio (ANVS) +250%.Jiuzi Holdings (JZXN) +27%.Longeveron (LGVN) +25%.Wah Fu Education (WAFU) +22%.Mesa Royalty Trust (MTR) +20%.Gracell Biotechnologies (GRCL) +20%.Obalon Therapeutics (OBLN) +16%.Yalla Group (YALA) +16%.VOC Energy Trust (VOC) +12%.Cyclo Therapeut...

Gainers: Annovis Bio ANVS +112%, Gracell Biotechnologies (GRCL) +24%, Metacrine MTCR +16%, Sensei Biotherapeutics (SNSE) +14%, Longeveron (LGVN) +12%.Losers: Precipio (PRPO) -12%, Cullinan Oncology CGEM -8%, Navidea Biopharmaceutical...